A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Combination chemo/radiotherapy trials in advanced/recurrent endometrial cancer are ongoing.
The optimal radiation modality, chemotherapeutic agents, and sequence of these regimens for
the treatment of UPSC are yet to be established. A retrospective review of 16 patients
treated at our institution with the sequential use of radiation "sandwiched" between
paclitaxel/platinum chemotherapy found only one patient to have recurred at 16 months with a
median follow-up of 15 months (range 6-33 months). The regimen was well tolerated. Eight of
the sixteen patients (50%) developed grade 3 neutropenia following cycle 4 of chemotherapy,
two of which required a 1 week treatment delay. There were no cases of grade 3 or 4
thrombocytopenia noted. There was no febrile neutropenia and no hospital admissions for
toxicity. There were no observed grade 3 or 4 non-hematologic toxicities. With the median
follow up of 15 months, we have not observed late toxicities.
Given these favorable preliminary findings, supported by recently published data documenting
efficacy of the "sandwich" multimodality technique in other difficult uterine malignancies
(malignant mixed mullerian tumors), we propose to study this combination of chemotherapy and
radiation prospectively. Our aim is to better evaluate patterns of recurrence and possible
benefits in progression-free and overall survival.